UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________________________________________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of ~~the~~The Securities Exchange Act of 1934

~~____________________________________________________________~~May 11, 2016

Date of Report (Date of earliest event reported)~~: February 22, 2016~~

GALILEO LIFE SCIENCES, INC.

(Exact Name of Registrant as Specified in Charter)

MODERN MOBILITY AIDS, INC.

(Former name or former address, if changed since last report)

Nevada	333-168983	27-4677038
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

First Canadian Place, Suite 350 Toronto, Ontario Canada		M5X1C1
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (586) 530-5605

Copies to:

Arthur S. Marcus, Esq.

Sichenzia Ross Friedman Ference LLP

61 Broadway, 32nd Floor

New York, New York 10006

(212) 930-9700

(212) 930-9725 (fax)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

□ ¨ Written ~~communications~~communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ ¨ Soliciting material pursuant to Rule 14a-12 under the ~~Exchange~~Securities Act (17 CFR 240.14a-12)

□ ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

□ ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~ENTRY ~~4.01 Changes~~INTO inMATERIAL ~~Registrant’s~~DEFINITIVE ~~Certifying Accountant.~~AGREEMENT

~~(a) Cutler~~Item ~~& Co~~1.,01 ~~LLC~~Entry ~~(“Cutler”)~~into ~~has~~Material ~~informed~~Definitive Galileo Life Sciences, Inc. (the “Company”) that it has merged its SEC auditing practice with Pritchett, Siler & Hardy PC (“Pritchett Siler”). As a result of the transaction, Cutler has resigned as the Company’s independent registered public accounting firm. On February 11, 2016, the Company’s Board of Directors approved the engagement of Pritchett Siler as the Company’s independent registered public accounting firm. Agreement

~~The~~Galileo ~~audit~~Life ~~reports~~Sciences ofInc. ~~Cutler~~has onentered ~~the~~into ~~consolidated~~an ~~financial~~agreement ~~statements~~to ofmerge ~~the~~with ~~Company~~Novo ~~for the years ended June 30~~Healthnet, ~~2014~~Canada’s ~~and~~third ~~2013~~largest ~~did~~provider ~~not contain any adverse opinion or disclaimer~~ of ~~opinion,~~Whole ~~nor~~Health ~~was~~Services ~~they~~including ~~qualified or modified as to uncertainty~~physiotherapy, ~~audit~~massage ~~scope~~therapy, orand ~~accounting~~chiropractic ~~principles~~dealing ~~except~~with ~~that~~rehabilitation ~~the~~medicine ~~audit~~and ~~reports~~chronic ~~contained~~pain anmanagement ~~uncertainty~~solutions ~~about~~for ~~the~~improved ~~Company’s ability to continue as a going concern~~functioning.

~~During~~Novo ~~the years~~Healthnet ~~ended~~has ~~June~~a ~~30,~~chain ~~2014~~of ~~and~~114 ~~2013~~clinics, ~~the~~many ~~interim~~of ~~period~~which ~~through~~are ~~September~~owned ~~30, 2014~~ and ~~subsequently~~operated ~~through~~while ~~February~~the ~~11,~~remainder ~~2016 (i)~~are ~~there were no disagreements with Cutler on any matter of accounting principles or practices~~affiliates, ~~financial~~staffed ~~statement~~and ~~disclosure,~~administered orby ~~auditing~~licensed ~~scope~~health orcare ~~procedures~~professionals. Already ~~that~~100,000 ifpatients ~~not~~annually ~~resolved~~visit tothese ~~Cutler’s~~health ~~satisfaction,~~clinics ~~would~~across have caused Cutler to make reference in connection to their opinion to the subject matter of the disagreement and (ii) there were no “reportable events” as defined in Item 304(a)(1)(v) of Regulation S-K.Canada

~~The~~Novo ~~Company~~Healthnet ~~has~~is ~~provided~~partnered ~~Cutler~~ with a ~~copy~~licensed ofproducer ~~this Current Report on Form 8-K~~ and ~~requested~~distributor ~~that~~of ~~Cutler~~cannabis ~~furnish~~products ~~the Company with a letter addressed to the Securities~~ and ~~Exchange~~derivates. ~~Commission~~Novo ~~stating~~Healthnet ~~whether~~also ithas ~~agrees~~exclusive ~~with~~marketing ~~the statements made by the Company herein~~ and, ifdistribution ~~not,~~rights ~~stating the respects in which it does not agree. The letter from Cutler~~ to ~~the~~an ~~Securities~~on-line ~~and~~virtual ~~Exchange~~physician ~~Commission~~access ~~dated~~system asacross ofCanada ~~February~~for ~~22,~~all ~~2016,~~cannabinoid-based ~~is attached as Exhibit 16.1 to this Current Report.~~products

~~(b) As~~Novo ~~noted~~Health ~~above,~~and onits ~~February~~partner ~~11,~~have ~~2016,~~a ~~the~~roster ~~Company’s Board~~ of ~~Directors~~referring ~~approved~~physicians ~~the engagement of Pritchett Siler as the Company’s independent registered public accounting firm. During the years ended June 30, 2014~~ and ~~2013,~~ the ~~interim~~integrated ~~period~~system ~~through~~of ~~September 30, 2014 and subsequently through February 11, 2016, neither~~ the ~~Company~~three ~~nor~~combined tooperations ~~the~~will ~~Company’s~~provide ~~knowledge~~patients ~~anyone~~with ~~acting~~both on-site ~~behalf~~and ofremote ~~the~~diagnosis ~~Company~~by ~~consulted~~Canadian ~~with~~physicians ~~Pritchett~~able ~~Siler regarding either (i) the application of accounting principles~~ to aissue ~~specified~~prescriptions ~~transaction~~for ~~(either~~cannabinoid ~~completed~~based or proposed), (ii) the type of audit opinion that might be rendered on the Company’s financial statements, or (iii) any matter that was either the subject matter of a “disagreement,” as described in Item 304(a)(1) of Regulation S-K, or a “reportable eventmedicine.”

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Exhibit
16.1	Letter from Cutler & Co., LLC, dated February 22, 2016.

~~SIGNATURES~~Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	~~GALILEO LIFE SCIENCES, INC.~~	GALILEO LIFE SCIENCES, INC.
Date: February 22, 2016	By:	/s/ Declan French
Date: May 11, 2016		(Registrant)
		Declan French
		/s/ Declan French
		Chief Executive Officer
		Declan French Chief Executive Officer

Filing Compare · Modern Mobility Aids, Inc.